*Article Updated 04/06/2020 — Coronavirus disease (COVID-19) is an emerging global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019 and by March 2020 it was reported that it had spread to several countries across the world. [Read more…]
COVID-19 Vaccine: IntelliStem Technologies Announces Successful Development of Peptide-Based Vaccine Against COVID-19
TORONTO, ON – April 6th, 2020—INTELLiSTEM Technologies Inc, a biotechnology company pioneering cellular vaccines and peptide therapeutics, announced the successful development of a peptide-based vaccine (IPT-001) intended for human use against COVID-19.
IPT-001 is a peptide-based vaccine developed using the novel coronavirus COVID-19. It was engineered using INTELLiPEPTIDOME™ Platform to target both the Spike (S) and Nucleocapsid (N) proteins. [Read more…]
Citius to License Novellus’ iPSC-derived MSCs for COVID-19 Related Complications
– Novellus’ patented mRNA-based cell-reprogramming technology creates MSCs with superior immunomodulatory properties
– Novellus’ iPSC-derived MSCs have manufacturing advantages over primary adult, donor-derived MSCs, allowing for larger supply, faster scale-up, and a more consistent cellular product
– MSCs may remedy the cytokine storm that triggers acute respiratory distress syndrome (ARDS) in COVID-19 patients
Aspire Announces Filing of a Pre-IND Meeting Request with U.S. FDA and a Pre-CTA Meeting Request with Health Canada for its ACT-20 Cellular Therapy against COVID-19 Pneumonia
ORLANDO, Florida, March 31st, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered manufacturing facility specialized in the development and manufacturing of cell-based therapies, is pleased to announce that it has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA and Pre-CTA (Clinical Trial Application) with Health Canada. A complete briefing package accompanied the meeting requests. This initiates formal communications between Aspire and both the U.S. FDA and Health Canada regarding development of the Company’s cellular therapy, ACT-20 for the treatment of severe COVID-19 Pneumonia. [Read more…]
COVID-19 News: Role of Cell Therapies in COVID-19 Complications
Coronavirus disease (COVID-19) is a global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019, and by March 2020, it had spread to at least 180 countries and territories worldwide. [Read more…]
